Clinical Study ResultsUBX1325 demonstrated vision gains comparable and statistically non-inferior to aflibercept at week 36 considering difficult to-treat DME patients with favorable safety and tolerability.

Subgroup PerformanceUBX1325 generally outperformed aflibercept in the pre-specified subgroup entering the study with CST <400 microns, reflecting 60% of enrolled patients.

Treatment EfficiencyApproximately 40% of UBX1325 patients did not require supplemental anti-VEGF through week 36, supporting the novel retinal mechanism.

Bears Say

Clinical Study EndpointThe previously announced primary endpoint miss for the Phase 2B ASPIRE study comparing UBX1325 and aflibercept in diabetic macular edema patients, not achieving non-inferiority at the average of weeks 20 and 24 primary analysis.

Patient Group ImbalanceThere were considerably more Vabysmo (faricimab) patients in the UBX1325 group, compared to aflibercept, reflecting a relevant imbalance.

Unity Biotechnology News

Unity Biotechnology Files Dissolution Certificate Amid Cost-Cutting

An announcement from Unity Biotechnology ( ($UNBX) ) is now available. On September 24, 2025, Unity Biotechnology, Inc....

24h ago

UNBX

Unity Biotechnology Approves Company Liquidation Plan

Unity Biotechnology ( ($UNBX) ) has shared an announcement. On September 18, 2025, Unity Biotechnology held a special...

8d ago

UNBX

UBX Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Unity Biotech (UBX) is scheduled to report 2nd quarter earnings on 08/12/2025. Regarding Q2 estimates, Wall Street analysts...

2M ago

UNBX

Unity Biotechnology Alters Voting Dynamics with New Stock

Unity Biotechnology ( ($UNBX) ) has provided an announcement. On July 22, 2025, Unity Biotechnology, Inc. entered into...

2M ago

UNBX

UNBX FAQ

What was Unity Biotechnology’s price range in the past 12 months?

Unity Biotechnology lowest stock price was $0.05 and its highest was $3.10 in the past 12 months.

What is Unity Biotechnology’s market cap?

Unity Biotechnology’s market cap is $1.03M.

When is Unity Biotechnology’s upcoming earnings report date?

Unity Biotechnology’s upcoming earnings report date is Nov 05, 2025 which is in 39 days.

How were Unity Biotechnology’s earnings last quarter?

Currently, no data Available

Is Unity Biotechnology overvalued?

According to Wall Street analysts Unity Biotechnology’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Unity Biotechnology pay dividends?

Unity Biotechnology does not currently pay dividends.

What is Unity Biotechnology’s EPS estimate?

Unity Biotechnology’s EPS estimate is 0.

How many shares outstanding does Unity Biotechnology have?

Unity Biotechnology has 17,212,172 shares outstanding.

What happened to Unity Biotechnology’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Unity Biotechnology?

Currently, no hedge funds are holding shares in UNBX

Company Description

Unity Biotechnology

Unity Biotechnology (UBX) is a biotechnology company focused on developing therapeutics to treat age-related diseases. The company's primary aim is to extend healthspan, the period during which individuals remain healthy and free from age-related ailments. Unity Biotechnology's core products target senescent cells, which are cells that have stopped dividing and can contribute to various age-related diseases. By focusing on senescence biology, Unity seeks to develop innovative treatments for conditions such as osteoarthritis and other chronic diseases associated with aging.